To include your compound in the COVID-19 Resource Center, submit it here.

Raxone idebenone regulatory update

Santhera said FDA would not support its plan to submit an NDA for Raxone idebenone to treat Duchenne muscular dystrophy (DMD) without data

Read the full 230 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE